Acute Ischemic Stroke — Xingnaojing for Moderate-to-severe Acute Ischemic Stroke (XMAS)
Citation(s)
Xingnaojing for Moderate-to-severe Acute Ischemic Stroke (XMAS): A Multicenter, Prospective, Randomized, Open-label, Blinded Endpoint Clinical Trial.